医学
视神经脊髓炎
水通道蛋白4
光谱紊乱
多发性硬化
视神经炎
脊髓炎
皮肤病科
横贯性脊髓炎
作者
Nadja Siebert,Ankelien Solveig Duchow,Friedemann Paul,Carmen Infante‐Duarte,Judith Bellmann–Strobl
出处
期刊:Drugs of Today
[Prous Science]
日期:2021-01-01
卷期号:57 (5): 321-321
被引量:6
标识
DOI:10.1358/dot.2021.57.5.3265453
摘要
Until recently, the use of preventative immunotherapy in neuromyelitis optica spectrum disorders (NMOSD) was based on observational studies and clinical experiences. Meanwhile, the first drugs, among others the monoclonal antibody inebilizumab, were approved for the treatment of aquaporin-4 (AQP4) antibody-positive NMOSD. Inebilizumab binds to the CD19 antigen on B cells and leads to B-cell depletion. The first two dosages of 300 mg inebilizumab are administered intravenously at an interval of 2 weeks followed by further infusions every 6 months. In the placebo-controlled pivotal phase II/III study N-MOmentum, inebilizumab significantly prolonged the time to a first adjudicated relapse in AQP4 antibody-positive patients compared with placebo. The most frequent side effects were infusion reactions, urinary and respiratory tract infections, and arthralgia. This review presents data on clinical and preclinical pharmacology, administration, safety aspects and clinical trials of inebilizumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI